{"version":"1.0","type":"link","title":"Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group.","author_name":"Dinkel H 외","author_url":"https://prs-insight.online/author/Dinkel%20H","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/166739","thumbnail_width":1200,"thumbnail_height":630}